XTX Topco’s BioNexus Gene Lab BGLC Stock Holding History

XTX Topco’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,283	Closed	-$9.17K	–	2421
2024 Q4	$9.17K	Buy	+3,283	New	+$10.8K	﹤0.01%	2160

Other funds holding BGLC

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco's BGLC Position: Q1 2025 in Review

XTX Topco sold out of BioNexus Gene Lab (BGLC) in Q1 2025, closing a stake of 3,283 shares — an estimated $9.17K sold.

XTX Topco first reported a position in BGLC in Q4 2024 and held it in 1 quarter. The position peaked at $9.17K in Q4 2024. 3 funds tracked by Wall St. Rank hold BGLC as of Q1 2025.

XTX Topco reported no remaining BioNexus Gene Lab position as of Q1 2025 after selling out during the quarter.
XTX Topco sold 3,283 BioNexus Gene Lab shares in Q1 2025, an estimated $9.17K.
XTX Topco first reported a position in BioNexus Gene Lab in Q4 2024 and held it in 1 quarter.
XTX Topco's BioNexus Gene Lab position peaked at $9.17K in Q4 2024.
3 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q1 2025.

Based on XTX Topco's 13F filing for Q1 2025, filed 8 May 2025.